Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
29 Janeiro 2024 - 10:00AM
Cingulate Inc. (NASDAQ:
CING), a biopharmaceutical company utilizing its
proprietary Precision Timed Release™ (PTR™) drug delivery platform
technology to build and advance a pipeline of next-generation
pharmaceutical products, announced today that it has promoted
Controller Jennifer Callahan to Chief Financial Officer, succeeding
longtime CFO Lou Van Horn who retired from the company in December.
“Today we are pleased to welcome Jennifer Callahan to the
C-Suite, and thank Lou Van Horn for his commitment, hard work, and
guidance as Cingulate’s CFO through many important milestones,”
stated Cingulate Chairman and CEO Shane J. Schaffer. “Jenny has
worked closely with Lou and is a valued and trusted member of our
management. Her leadership and expertise were instrumental during
Cingulate’s IPO, and we look forward to a seamless transition as we
begin this new chapter.”
Callahan, who brings decades of accounting and financial
experience to Cingulate’s C-Suite, said she’s excited to lead the
finance team into the future and hopes to help the company raise
capital in an efficient and timely manner.
“It’s been a pleasure advancing the Cingulate mission for the
past seven years, and I am honored to be named its next Chief
Financial Officer,” Callahan said. “As we move forward, capital
remains imperative to the long-term success of Cingulate, and we
will seek to strengthen our balance sheet through both traditional
and non-dilutive transactions.”
About Cingulate Inc.Cingulate Inc. (NASDAQ:
CING), is a biopharmaceutical company utilizing its proprietary PTR
drug delivery platform technology to build and advance a pipeline
of next-generation pharmaceutical products, designed to improve the
lives of patients suffering from frequently diagnosed conditions
characterized by burdensome daily dosing regimens and suboptimal
treatment outcomes. With an initial focus on the treatment of ADHD,
Cingulate is identifying and evaluating additional therapeutic
areas where PTR technology may be employed to develop future
product candidates, including to treat anxiety disorders. Cingulate
is headquartered in Kansas City. For more information
visit Cingulate.com.
Forward-Looking Statements This press
release contains “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements include all statements, other than
statements of historical fact, regarding our current views and
assumptions with respect to future events regarding our business,
including statements with respect to our plans, assumptions,
expectations, beliefs and objectives with respect to product
development, clinical studies, clinical and regulatory timelines,
market opportunity, competitive position, business strategies,
potential growth opportunities and other statements that are
predictive in nature. These statements are generally identified by
the use of such words as “may,” “could,” “should,” “would,”
“believe,” “anticipate,” “forecast,” “estimate,” “expect,”
“intend,” “plan,” “continue,” “outlook,” “will,” “potential” and
similar statements of a future or forward-looking nature. Readers
are cautioned that any forward-looking information provided by us
or on our behalf is not a guarantee of future performance. Actual
results may differ materially from those contained in these
forward-looking statements as a result of various factors disclosed
in our filings with the Securities and Exchange Commission (SEC),
including the “Risk Factors” section of our Annual Report on Form
10-K filed with the SEC on March 10, 2023. All forward-looking
statements speak only as of the date on which they are made, and we
undertake no duty to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except to the extent required by law.
Investor Relations:Thomas DaltonVice President,
Investor & Public Relations,
Cingulatetdalton@cingulate.com(913) 942-2301
Matt KrepsDarrow
Associatesmkreps@darrowir.com (214)
597-8200
Cingulate (NASDAQ:CINGW)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Cingulate (NASDAQ:CINGW)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024